Compare EXK & IDYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EXK | IDYA |
|---|---|---|
| Founded | 1981 | 2015 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5B | 2.9B |
| IPO Year | N/A | 2019 |
| Metric | EXK | IDYA |
|---|---|---|
| Price | $11.34 | $32.17 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 14 |
| Target Price | $13.31 | ★ $49.67 |
| AVG Volume (30 Days) | ★ 17.4M | 858.2K |
| Earning Date | 03-10-2026 | 02-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $337,137,000.00 | $214,834,000.00 |
| Revenue This Year | $111.57 | $2,688.43 |
| Revenue Next Year | $64.09 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 49.22 | ★ 5377.66 |
| 52 Week Low | $2.95 | $13.45 |
| 52 Week High | $15.15 | $39.28 |
| Indicator | EXK | IDYA |
|---|---|---|
| Relative Strength Index (RSI) | 47.57 | 43.58 |
| Support Level | $10.40 | $31.54 |
| Resistance Level | $12.06 | $34.66 |
| Average True Range (ATR) | 0.98 | 1.39 |
| MACD | -0.34 | -0.32 |
| Stochastic Oscillator | 13.47 | 25.17 |
Endeavour Silver Corp is a Canadian mineral company engaged in the evaluation, acquisition, exploration, development, and exploitation of precious metal properties in Mexico and Chile. The Company has two operating mining segments which are located in Mexico, Guanacevi and Bolanitos. The company has one development project in Mexico, Terronera, as well as Exploration and Corporate segments. The Exploration segment consists of projects in the exploration and evaluation phases in Mexico, Chile, and the USA.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275/GSK959 (Werner Helicase), IDE161 (PARG), and IDE705/GSK101 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.